R&D Systems Inc. Tocris Bioscience Boston Biochem

NMDA Receptors

More Information »NMDA receptors are members of the ionotropic class of glutamate receptors, which also includes Kainate and AMPA receptors. NMDA receptors consist of NR1 subunits combined with NR2 (A-D) or NR3 (A-B) subunits. The ligand-gated channel is permeable to cations.

NMDA Receptor Products

Agonists
Cat.No.
Product Name / Activity
0186 cis-ACPD
Potent NMDA agonist. Also group II mGluR agonist
0213 D-Aspartic acid
NMDA agonist
0214 L-Aspartic acid
NMDA agonist
0216 L-Cysteinesulfinic acid
NMDA and mGlu agonist
3406 GLYX 13
NMDA receptor partial agonist; acts at the glycine site
0281 (R)-(+)-HA-966
NMDA partial agonist/antagonist, acts at glycine site
0197 Homoquinolinic acid
Selective, potent NMDA agonist
0285 Ibotenic acid
Non-selective NMDA agonist
2277 MNI-caged-D-aspartate
Caged D-aspartate; NMDA agonist
0114 NMDA
Selective NMDA agonist
0959 Spermidine trihydrochloride
Agonist at polyamine site
0312 (RS)-(Tetrazol-5-yl)glycine
Highly potent NMDA receptor agonist
Antagonists
Cat.No.
Product Name / Activity
0258 ACBC
NMDA antagonist, acts at glycine site
3693 DL-AP5 Sodium salt
Sodium salt of DL-AP5 (Cat. No. 0105)
0106 D-AP5
Potent, selective NMDA antagonist. More active form of DL-AP5 (Cat. No. 0105)
0105 DL-AP5
Potent, selective NMDA antagonist
0107 L-AP5
Potent, selective NMDA antagonist. Less active form of DL-AP5 (Cat. No. 0105)
0164 D-AP7
Specific NMDA antagonist. More active form of DL-AP7 (Cat. No. 0104)
0104 DL-AP7
Specific NMDA antagonist
0389 Arcaine sulfate
Competitive NMDA antagonist
0322 (R)-4-Carboxyphenylglycine
Moderately potent NMDA antagonist
1469 CGP 37849
Potent selective NMDA antagonist
1409 CGP 39551
Potent, selective and competitive NMDA antagonist
1493 CGP 78608 hydrochloride
Potent, selective glycine-site NMDA antagonist
1241 CGS 19755
Potent, competitive NMDA antagonist
3697 7-Chlorokynurenic acid sodium salt
Sodium salt of 7-Chlorokynurenic acid (Cat. No. 0237)
0237 7-Chlorokynurenic acid
NMDA antagonist, acts glycine site
0817 (2R,3S)-Chlorpheg
Weak NMDA antagonist
0190 CNQX
NMDA antagonist, acts glycine site. Also AMPA/kainate antagonist
2456 Co 101244 hydrochloride
Highly selective NR2B antagonist
4136 Conantokin G
NR2B-selective NMDA receptor antagonist
3125 Conantokin-R
Potent non-competitive NMDA receptor antagonist
3122 Conantokin-T
Non-competitive NMDA receptor antagonist
0247 (R)-CPP
Potent NMDA antagonist. More active enantiomer of (RS)-CPP (Cat. No. 0173)
0173 (RS)-CPP
Potent NMDA antagonist
1265 D-CPP-ene
Potent, competitive NMDA antagonist
3071 Dextromethorphan hydrobromide
NMDA receptor antagonist
0286 5,7-Dichlorokynurenic acid
Potent NMDA antagonist, acts glycine site
3698 5,7-Dichlorokynurenic acid sodium salt
Sodium salt of 5,7-Dichlorokynurenic acid (Cat. No. 0286). Potent NMDA antagonist, acts at glycine site
0360 (±)-1-(1,2-Diphenylethyl)piperidine maleate
NMDA antagonist, acts ion channel site
4491 DQP 1105
Selective NR2C/NR2D receptor antagonist
2195 Eliprodil
Non-competitive NR2B-selective NMDA antagonist
0869 Felbamate
NMDA antagonist, acts glycine site
2867 Flupirtine maleate
Indirect NMDA receptor antagonist
2348 Gavestinel
Potent and selective glycine site antagonist. Orally available and active in vivo
0282 (S)-(-)-HA-966
NMDA antagonist/partial agonist
2861 HU 211
NMDA receptor antagonist. Also NF-κB inhibitor
0290 N-(4-Hydroxyphenylacetyl)spermine
Wasp toxin analog
0545 Ifenprodil hemitartrate
Non-competitive NMDA antagonist. Also σ ligand
2892 threo Ifenprodil hemitartrate
NR2B-selective NMDA antagonist. Also σ agonist
3131 Ketamine hydrochloride
Non-competitive NMDA receptor antagonist
4379 (S)-(+)-Ketamine hydrochloride
NMDA receptor antagonist; enantiomer of ketamine hydrochloride (Cat. No. 3131)
0742 L-689,560
Very potent NMDA antagonist
0705 L-701,252
NMDA antagonist, acts glycine site
0907 L-701,324
NMDA antagonist, acts at glycine site
0840 Loperamide hydrochloride
NMDA antagonist, reduces Ca2+ flux
1521 LY 233053
Competitive NMDA receptor antagonist
1019 LY 235959
Competitive NMDA antagonist
0773 Memantine hydrochloride
NMDA antagonist; acts at ion channel site
0955 (-)-MK 801 maleate
NMDA antagonist, less active enantiomer
0924 (+)-MK 801 maleate
Non-competitive NMDA antagonist, acts at ion channel site
1970 Norketamine hydrochloride
Potent, non-competitive NMDA antagonist
4230 NPEC-caged-D-AP5
Caged D-AP5 (Cat.No. 0106); NMDA antagonist
3277 Pentamidine isethionate
Antimicrobial that antagonizes NMDA receptors
2557 Phencyclidine hydrochloride
Non-competitive NMDA receptor antagonist
2273 PMPA (NMDA antagonist)
Competitive NMDA antagonist
2530 PPDA
Subtype-selective NR2C/NR2D antagonist
2274 PPPA
Competitive NR2A antagonist
4801 QNZ 46
NR2C/NR2D-selective NMDA receptor non-competitive antagonist
1622 Remacemide hydrochloride
NMDA antagonist; blocks ion channel and allosteric modulatory site
2005 Ro 04-5595 hydrochloride
Selective NR2B antagonist
1594 Ro 25-6981 maleate
Subtype-selective NR2B antagonist
3254 Ro 61-8048
NMDA antagonist; increases kynurenic acid levels
3343 Ro 8-4304 hydrochloride
Selective NR2B antagonist
1251 SDZ 220-040
Potent, competitive NMDA antagonist
1250 SDZ 220-581
Competitive NMDA antagonist
0635 Synthalin sulfate
Non-competitive NMDA antagonist
4154 TCN 201
Selective NR1/NR2A receptor antagonist
4163 TCN 213
NMDA antagonist; selective for NR2A over NR2B
4072 TCN 237 dihydrochloride
Highly potent and selective NR2B antagonist
2782 TCS 46b
Orally active, subtype-selective NR1A/NR2B antagonist
3322 ZD 9379
Brain penetrant NMDA antagonist, acts at glycine site
Ligand Sets
Cat.No.
Product Name / Activity
1825 Mixed NMDA Receptor Tocriset™
Selection of 5 mixed NMDA receptor ligands (Cat. Nos. 0114, 0312, 0106, 0924 and 1241)
1823 NMDA Receptor - Glycine Site Tocriset™
Selection of 5 NMDA receptor (glycine site) ligands (Cat. Nos. 0219, 0281, 0742, 1493 and 0237)
Other
Cat.No.
Product Name / Activity
1238 CCMQ
Used to characterize NR2B-containing NMDA receptors
4105 CIQ
Potentiator of NMDA receptors containing NR2C/NR2D
0219 Glycine
Endogenous potentiator, co-transmitter
1636 IEM 1460
Open-channel blocker of NMDA currents. Also blocks AMPA currents
2224 MNI-caged-NMDA
Caged NMDA
2213 N20C hydrochloride
Non-competitive NMDA receptor open-channel blocker
2851 Nefiracetam
Cognitive enhancer; potentiates NMDA currents
0225 Quinolinic acid
Endogenous NMDA agonist and transmitter candidate
0226 D-Serine
Potentiator, acts glycine site
0958 Spermine tetrahydrochloride
Modulator at polyamine site
Related Categories

Quick Order

Find multiple products by catalog number

divider line

Pain Research Product Guide

Pain Research Guide

Highlights over 280 products for Pain research. Request copy or view PDF today.

divider line

Neurodegeneration Research Product Guide

Neurodegeneration Research Guide

Highlights over 250 products for neurodegeneration research. Request a copy or view PDF today.

divider line

Learning and Memory

Written by Clea Warburton and Zafar Bashir

Learning and Memory Poster

An overview of the cellular mechanisms underlying recognition memory and its links to long-term depression. Request a copy or view PDF today.

divider line

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

Neuroprotection Poster

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

divider line

Peripheral Sensitization

Written by Grant D. Nicol and Michael R. Vasko

Pain Poster

A summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. Request a copy or view PDF today.

divider line

Neurobiology of Parkinson's Disease

Written by A. Schapira

Parkinson's Poster

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.

divider line

Antidepressants - Current and Future Targets

Written by P. Skolnich et al

Antidepressants poster

'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

The Neurobiology of Alzheimer's Disease

Written by Alan Palmer

Alzheimer's Poster

'The Neurobiology of Alzheimer's Disease' summarizes structural and functional changes observed in the progression of AD.

divider line

New Product Guide

NPG

Highlights 140 new products added in the first half of 2014. Request a copy or view PDF today.

divider line

Bio-Techne Events

Annual Meeting of the Japan Neuroscience Society

Annual Meeting of the Japan Neuroscience Society

September 11 - 13, 2014

Yokohama, Japan